Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter's syndrome.
This report concerns two patients with Bartter's syndrome who were treated with propranolol, spironolactone, and potassium supplements. When ibuprofen was added to this regimen, potassium supplements were no longer required. In both patients, plasma renin activity decreased, plasma volumes increased, and a "catch-up" in linear growth ensued. This report confirms others that indicate prostaglandin synthetase inhibitors are a useful adjunct in the therapy of Bartter's syndrome.
D000293:Adolescent; D001477:Bartter Syndrome / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D006128:Growth / Q000187:drug effects; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy*; D007052:Ibuprofen / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D011188:Potassium / Q000097:blood; D011433:Propranolol / Q000008:administration & dosage* / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors
D013148:Spironolactone; D011433:Propranolol; D012083:Renin; D011188:Potassium; D007052:Ibuprofen